Design and rationale for RE-VERSE AD: a phase 3 study of idarucizumab, a specific reversal agent for dabigatran
Idarucizumab, a Fab fragment directed against dabigatran, produced rapid and complete reversal of the anticoagulation effect of dabigatran in animals and in healthy volunteers. The Study of the REVERS al E ffects of Idarucizumab in Patients on A ctive D abigatran (RE-VERSE AD™) is a global phase 3 p...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2015
|
| In: |
Thrombosis and haemostasis
Year: 2017, Jahrgang: 114, Heft: 1, Pages: 198-205 |
| ISSN: | 2567-689X |
| DOI: | 10.1160/TH15-03-0192 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1160/TH15-03-0192 Verlag, lizenzpflichtig, Volltext: http://www.thieme-connect.de/DOI/DOI?10.1160/TH15-03-0192 
|
| Verfasserangaben: | Charles V. Pollack Jr, Paul A. Reilly, Richard Bernstein, Robert Dubiel, John Eikelboom, Stephan Glund, Menno V. Huisman, Elaine Hylek, Chak-Wah Kam, Pieter W. Kamphuisen, Joerg Kreuzer, Jerrold H. Levy, Frank Sellke, Joachim Stangier, Thorsten Steiner, Bushi Wang, Jeffrey I. Weitz |
MARC
| LEADER | 00000caa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 1725257998 | ||
| 003 | DE-627 | ||
| 005 | 20220818154152.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200722r20152017xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1160/TH15-03-0192 |2 doi | |
| 035 | |a (DE-627)1725257998 | ||
| 035 | |a (DE-599)KXP1725257998 | ||
| 035 | |a (OCoLC)1341346983 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Pollack, Charles V. |e VerfasserIn |0 (DE-588)140620974 |0 (DE-627)703735160 |0 (DE-576)319144860 |4 aut | |
| 245 | 1 | 0 | |a Design and rationale for RE-VERSE AD |b a phase 3 study of idarucizumab, a specific reversal agent for dabigatran |c Charles V. Pollack Jr, Paul A. Reilly, Richard Bernstein, Robert Dubiel, John Eikelboom, Stephan Glund, Menno V. Huisman, Elaine Hylek, Chak-Wah Kam, Pieter W. Kamphuisen, Joerg Kreuzer, Jerrold H. Levy, Frank Sellke, Joachim Stangier, Thorsten Steiner, Bushi Wang, Jeffrey I. Weitz |
| 264 | 1 | |c 2015 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Publikationsdatum: 22. November 2017 | ||
| 500 | |a Gesehen am 22.07.2020 | ||
| 520 | |a Idarucizumab, a Fab fragment directed against dabigatran, produced rapid and complete reversal of the anticoagulation effect of dabigatran in animals and in healthy volunteers. The Study of the REVERS al E ffects of Idarucizumab in Patients on A ctive D abigatran (RE-VERSE AD™) is a global phase 3 prospective cohort study aimed at investigating idarucizumab in dabigatran-treated patients who present with uncontrollable or life-threatening bleeding, and in those requiring urgent surgery or intervention. We describe the rationale for, and design of the trial (clinicaltrials.gov NCT02104947). | ||
| 534 | |c 2017 | ||
| 700 | 1 | |a Reilly, Paul A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bernstein, Richard |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dubiel, Robert |e VerfasserIn |4 aut | |
| 700 | 1 | |a Eikelboom, John |e VerfasserIn |4 aut | |
| 700 | 1 | |a Glund, Stephan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Huisman, Menno V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hylek, Elaine |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kam, Chak-Wah |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kamphuisen, Pieter W. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kreuzer, Joerg |e VerfasserIn |4 aut | |
| 700 | 1 | |a Levy, Jerrold H. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sellke, Frank |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stangier, Joachim |e VerfasserIn |4 aut | |
| 700 | 1 | |a Steiner, Thorsten |d 1961- |e VerfasserIn |0 (DE-588)118107623 |0 (DE-627)079247407 |0 (DE-576)291718779 |4 aut | |
| 700 | 1 | |a Wang, Bushi |e VerfasserIn |4 aut | |
| 700 | 1 | |a Weitz, Jeffrey I. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Thrombosis and haemostasis |d Stuttgart : Thieme, 1976 |g 114(2015), 1, Seite 198-205 |h Online-Ressource |w (DE-627)302723188 |w (DE-600)1492370-1 |w (DE-576)079877362 |x 2567-689X |7 nnas |a Design and rationale for RE-VERSE AD a phase 3 study of idarucizumab, a specific reversal agent for dabigatran |
| 773 | 1 | 8 | |g volume:114 |g year:2015 |g number:1 |g pages:198-205 |g extent:8 |a Design and rationale for RE-VERSE AD a phase 3 study of idarucizumab, a specific reversal agent for dabigatran |
| 856 | 4 | 0 | |u https://doi.org/10.1160/TH15-03-0192 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://www.thieme-connect.de/DOI/DOI?10.1160/TH15-03-0192 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200722 | ||
| 993 | |a Article | ||
| 994 | |a 2015 | ||
| 998 | |g 118107623 |a Steiner, Thorsten |m 118107623:Steiner, Thorsten |d 910000 |d 911100 |e 910000PS118107623 |e 911100PS118107623 |k 0/910000/ |k 1/910000/911100/ |p 15 | ||
| 999 | |a KXP-PPN1725257998 |e 3727859776 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Publikationsdatum: 22. November 2017","Gesehen am 22.07.2020"],"person":[{"display":"Pollack, Charles V.","given":"Charles V.","role":"aut","family":"Pollack"},{"given":"Paul A.","display":"Reilly, Paul A.","role":"aut","family":"Reilly"},{"given":"Richard","display":"Bernstein, Richard","role":"aut","family":"Bernstein"},{"display":"Dubiel, Robert","given":"Robert","family":"Dubiel","role":"aut"},{"display":"Eikelboom, John","given":"John","family":"Eikelboom","role":"aut"},{"role":"aut","family":"Glund","display":"Glund, Stephan","given":"Stephan"},{"display":"Huisman, Menno V.","given":"Menno V.","family":"Huisman","role":"aut"},{"display":"Hylek, Elaine","given":"Elaine","family":"Hylek","role":"aut"},{"display":"Kam, Chak-Wah","given":"Chak-Wah","role":"aut","family":"Kam"},{"role":"aut","family":"Kamphuisen","display":"Kamphuisen, Pieter W.","given":"Pieter W."},{"family":"Kreuzer","role":"aut","given":"Joerg","display":"Kreuzer, Joerg"},{"given":"Jerrold H.","display":"Levy, Jerrold H.","role":"aut","family":"Levy"},{"role":"aut","family":"Sellke","given":"Frank","display":"Sellke, Frank"},{"family":"Stangier","role":"aut","display":"Stangier, Joachim","given":"Joachim"},{"role":"aut","family":"Steiner","given":"Thorsten","display":"Steiner, Thorsten"},{"given":"Bushi","display":"Wang, Bushi","role":"aut","family":"Wang"},{"display":"Weitz, Jeffrey I.","given":"Jeffrey I.","family":"Weitz","role":"aut"}],"recId":"1725257998","language":["eng"],"name":{"displayForm":["Charles V. Pollack Jr, Paul A. Reilly, Richard Bernstein, Robert Dubiel, John Eikelboom, Stephan Glund, Menno V. Huisman, Elaine Hylek, Chak-Wah Kam, Pieter W. Kamphuisen, Joerg Kreuzer, Jerrold H. Levy, Frank Sellke, Joachim Stangier, Thorsten Steiner, Bushi Wang, Jeffrey I. Weitz"]},"origin":[{"dateIssuedKey":"2015","dateIssuedDisp":"2015"}],"relHost":[{"disp":"Design and rationale for RE-VERSE AD a phase 3 study of idarucizumab, a specific reversal agent for dabigatranThrombosis and haemostasis","type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 15.06.2018"],"pubHistory":["35.1976 -"],"language":["eng"],"part":{"volume":"114","year":"2015","text":"114(2015), 1, Seite 198-205","pages":"198-205","extent":"8","issue":"1"},"origin":[{"dateIssuedDisp":"1976-","publisher":"Thieme ; Schattauer","publisherPlace":"Stuttgart ; Stuttgart","dateIssuedKey":"1976"}],"title":[{"title":"Thrombosis and haemostasis","subtitle":"journal of the International Society on Thrombosis and Haemostasis","title_sort":"Thrombosis and haemostasis"}],"id":{"zdb":["1492370-1"],"doi":["10.1055/s-00035024"],"eki":["302723188"],"issn":["2567-689X"]},"physDesc":[{"extent":"Online-Ressource"}],"recId":"302723188"}],"physDesc":[{"extent":"8 S."}],"id":{"doi":["10.1160/TH15-03-0192"],"eki":["1725257998"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title_sort":"Design and rationale for RE-VERSE AD","title":"Design and rationale for RE-VERSE AD","subtitle":"a phase 3 study of idarucizumab, a specific reversal agent for dabigatran"}]} | ||
| SRT | |a POLLACKCHADESIGNANDR2015 | ||